ReviewPharmaceutics2022
The Role of Atropine in Preventing Myopia Progression: An Update.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Biological mechanisms of atropine in myopia control (Review).Molecular medicine reports · 2026Pooled it
- Efficacy and safety of low-concentration atropine combined with orthokeratology for children with myopia: a systematic review and meta-analysis of randomized controlled trials.BMC ophthalmology · 2026Pooled it
- Myopia as a Global Public Health Challenge a Narrative Review.Life (Basel, Switzerland) · 2026Review
- Article
- The efficiency of 0.01% topical atropine on the myopia prevention in low refractive error population with different refractive errors: a retrospective cohort study.BMC ophthalmology · 2026Article
- Shaping the future of myopia: artificial intelligence for vitreoretinal complications of high and pathologic myopia.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- Current and Emerging Strategies for Myopia Control in Children: A Comprehensive Evidence-Based Review.Journal of clinical medicine · 2026Review
- Efficacy and Safety of Low-Concentration Atropine in Slowing Myopia Progression in Children in Japan: The Randomized, Double-Blind Phase II/III ORANGE Study.Ophthalmology science · 2026Article
- Prevalence of Refractive Errors, Myopic Macular Degeneration, and Associated Risk Factors in a Maltese Population-Based Study.Clinical optometry · 2026Article
- Current and emerging strategies for myopia control: a narrative review of optical, pharmacological, behavioural, and adjunctive therapies.Eye (London, England) · 2025Review
- A Personal Scientific Journey in Ophthalmology: Twenty-Five Years of Translating Research into Novel Therapies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The Daily and Two-Day Usage of Low-Dose Atropine on Myopic Control in a Low-Myopia Population.Journal of clinical medicine · 2025Article
- Refractive Development and Choroidal Vascularity in the Form-Deprivation Pigmented Rabbit Model.Translational vision science & technology · 2025Article
- New Advances in Drug Research for Myopia Control in Adolescents.Current drug targets · 2025Review
- Collagen is crucial target protein for scleral remodeling and biomechanical change in myopia progression and control.Heliyon · 2024Review
- Myopia Control in Caucasian Children with 0.01% Atropine Eye Drops: 1-Year Follow-Up Study.Medicina (Kaunas, Lithuania) · 2024Article
- Treatment of Rapid Progression of Myopia: Topical Atropine 0.05% and MF60 Contact Lenses.Vision (Basel, Switzerland) · 2024Article
- Retardation of myopia by atropine regimes.International journal of ophthalmology · 2024Review
- Short-term effects of ophthalmic topical 0.01% atropine on the ocular surface, pupil size, and subsequent subjective quality of vision in young myopic Chinese adults.Frontiers in medicine · 2024Article
- The optimal atropine concentration for myopia control in Chinese children: a systematic review and network Meta-analysis.International journal of ophthalmology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several approaches have been investigated for preventing myopia progression in children and teenagers. Among them, topical atropine has shown promising results and it is being adopted in clinical practice more and more frequently. However, the optimal formulation and treatment algorithm are still to be determined. We discuss the pharmacokinetic, pharmacodynamic, clinical, and tolerability profile revealed first by the multicenter, randomized ATOM 1 and 2 trials and, more recently, by the LAMP Study. Results from these trials confirmed the efficacy of low-concentration atropine with a concentration-dependent response. Although atropine at 0.025% and 0.05% concentrations has shown the most encouraging results in large-scale studies, these formulations are not yet commonplace in worldwide clinical practice. Moreover, their rebound effect and the possibility of reaching a stabilization effect have not been fully investigated with real-life studies. Thus, further larger-scale studies should better characterize the clinical efficacy of atropine over longer follow-up periods, in order to define the optimal dosage and treatment regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.